umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Tissue-specific dysregulation of cortisol regeneration by 11 beta HSD1 in obesity: has it promised too much?
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
2014 (Engelska)Ingår i: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 57, nr 6, s. 1100-1110Artikel, forskningsöversikt (Refereegranskat) Published
Abstract [en]

Cushing's syndrome, caused by increased production of cortisol, leads to metabolic dysfunction including visceral adiposity, hypertension, hyperlipidaemia and type 2 diabetes. The similarities with the metabolic syndrome are striking and major efforts have been made to find obesity-associated changes in the regulation of glucocorticoid action and synthesis, both at a systemic level and tissue level. Obesity is associated with tissue-specific alterations in glucocorticoid metabolism, with increased activity of the glucocorticoid-regenerating enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta HSD1) in subcutaneous adipose tissue and decreased conversion of cortisone to cortisol, interpreted as decreased 11 beta HSD1 activity, in the liver. In addition, genetic manipulation of 11 beta HSD1 activity in rodents can either induce (by overexpression of Hsd11b1, the gene encoding 11 beta HSD1) or prevent (by knocking out Hsd11b1) obesity and metabolic dysfunction. Taken together with earlier evidence that non-selective inhibitors of 11 beta HSD1 enhance insulin sensitivity, these results led to the hypothesis that inhibition of 11 beta HSD1 might be a promising target for treatment of the metabolic syndrome. Several selective 11 beta HSD1 inhibitors have now been developed and shown to improve metabolic dysfunction in patients with type 2 diabetes, but the small magnitude of the glucose-lowering effect has precluded their further commercial development. This review focuses on the role of 11 beta HSD1 as a tissue-specific regulator of cortisol exposure in obesity and type 2 diabetes in humans. We consider the potential of inhibition of 11 beta HSD1 as a therapeutic strategy that might address multiple complications in patients with type 2 diabetes, and provide our thoughts on future directions in this field.

Ort, förlag, år, upplaga, sidor
2014. Vol. 57, nr 6, s. 1100-1110
Nyckelord [en]
11 beta-Hydroxysteroid dehydrogenase type 1, 11 beta HSD1 inhibitors, Cortisol, Glucocorticoid metabolism, Obesity, Type 2 diabetes
Nationell ämneskategori
Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi
Identifikatorer
URN: urn:nbn:se:umu:diva-90761DOI: 10.1007/s00125-014-3228-6ISI: 000335922800002PubMedID: 24710966OAI: oai:DiVA.org:umu-90761DiVA, id: diva2:754382
Tillgänglig från: 2014-10-10 Skapad: 2014-07-01 Senast uppdaterad: 2018-06-07Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Stomby, AndreasOlsson, Tommy

Sök vidare i DiVA

Av författaren/redaktören
Stomby, AndreasOlsson, Tommy
Av organisationen
Medicin
I samma tidskrift
Diabetologia
Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 155 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf